Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

Merck said it plans to make the drug available in the U.S. ahead of the upcoming RSV season. Enflonsia joins a growing arsenal of tools to prevent RSV in infants.

RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants By Annika Kim Constantino, CNBC • Published June 26, 2025 • Updated on June 26, 2025 at 1:52 pm ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...